Literature DB >> 22049067

Epstein-Barr virus: an important vaccine target for cancer prevention.

Jeffrey I Cohen1, Anthony S Fauci, Harold Varmus, Gary J Nabel.   

Abstract

Participants at the February 2011 meeting at the U.S. National Institutes of Health on Epstein-Barr virus (EBV) vaccine research recommend that future clinical trials have two goals: prevention of infectious mononucleosis and EBV-associated cancers, facilitated by identification of disease-predictive surrogate markers.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22049067      PMCID： PMC3501269          DOI： 10.1126/scitranslmed.3002878

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  9 in total

Review 1.  Epstein-Barr virus infection.

Authors:  J I Cohen
Journal:  N Engl J Med       Date:  2000-08-17       Impact factor: 91.245

Review 2.  Immune defence against EBV and EBV-associated disease.

Authors:  Heather M Long; Graham S Taylor; Alan B Rickinson
Journal:  Curr Opin Immunol       Date:  2011-01-25       Impact factor: 7.486

3.  The global health burden of infection-associated cancers in the year 2002.

Authors:  Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

4.  HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma.

Authors:  Henrik Hjalgrim; Klaus Rostgaard; Paul C D Johnson; Annette Lake; Lesley Shield; Ann-Margaret Little; Karin Ekstrom-Smedby; Hans-Olov Adami; Bengt Glimelius; Stephen Hamilton-Dutoit; Eleanor Kane; G Malcolm Taylor; Alex McConnachie; Lars P Ryder; Christer Sundstrom; Paal Skytt Andersen; Ellen T Chang; Freda E Alexander; Mads Melbye; Ruth F Jarrett
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

Review 5.  Epstein-Barr virus and gastric carcinoma.

Authors:  Masashi Fukayama
Journal:  Pathol Int       Date:  2010-05       Impact factor: 2.534

6.  Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis.

Authors:  Suzanne L Elliott; Andreas Suhrbier; John J Miles; Greg Lawrence; Stephanie J Pye; Thuy T Le; Andrew Rosenstengel; Tam Nguyen; Anthony Allworth; Scott R Burrows; John Cox; David Pye; Denis J Moss; Mandvi Bharadwaj
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

7.  A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation.

Authors:  Lesley Rees; E Jane Tizard; Andrew J Morgan; W David Cubitt; Susan Finerty; Titilade A Oyewole-Eletu; Karen Owen; Collin Royed; Servi J Stevens; Rukshana C Shroff; Manjit K Tanday; A Douglas Wilson; Jaap M Middeldorp; Peter L Amlot; Neil M Steven
Journal:  Transplantation       Date:  2009-10-27       Impact factor: 4.939

8.  Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.

Authors:  Etienne M Sokal; Karel Hoppenbrouwers; Corinne Vandermeulen; Michel Moutschen; Philippe Léonard; Andre Moreels; Michèle Haumont; Alex Bollen; Françoise Smets; Martine Denis
Journal:  J Infect Dis       Date:  2007-12-15       Impact factor: 5.226

9.  Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine.

Authors:  M A Epstein; A J Morgan; S Finerty; B J Randle; J K Kirkwood
Journal:  Nature       Date:  1985 Nov 21-27       Impact factor: 49.962
  9 in total
  149 in total

1.  EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors.

Authors:  Robert E White; Patrick C Rämer; Kikkeri N Naresh; Sonja Meixlsperger; Laurie Pinaud; Cliona Rooney; Barbara Savoldo; Rita Coutinho; Csaba Bödör; John Gribben; Hazem A Ibrahim; Mark Bower; Jamie P Nourse; Maher K Gandhi; Jaap Middeldorp; Fathima Z Cader; Paul Murray; Christian Münz; Martin J Allday
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

Review 2.  Infectious Mononucleosis.

Authors:  Samantha K Dunmire; Kristin A Hogquist; Henry H Balfour
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

Review 3.  Leukaemia 'firsts' in cancer research and treatment.

Authors:  Mel Greaves
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

Review 4.  Epstein-Barr virus in the pathogenesis of oral cancers.

Authors:  J T Guidry; C E Birdwell; R S Scott
Journal:  Oral Dis       Date:  2017-04-18       Impact factor: 3.511

5.  Epstein-Barr virus replicating in epithelial cells.

Authors:  Lindsey M Hutt-Fletcher
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-10       Impact factor: 11.205

6.  (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves downregulation of latent membrane protein 1.

Authors:  Sufang Liu; Hongde Li; Min Tang; Ya Cao
Journal:  Exp Ther Med       Date:  2017-11-13       Impact factor: 2.447

7.  Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques.

Authors:  R Leskowitz; M H Fogg; X Y Zhou; A Kaur; E L V Silveira; F Villinger; P M Lieberman; F Wang; H C Ertl
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

8.  Invited commentary: Epstein-Barr virus-based screening for the early detection of nasopharyngeal carcinoma: a new frontier.

Authors:  Allan Hildesheim
Journal:  Am J Epidemiol       Date:  2012-12-19       Impact factor: 4.897

9.  S-Like-Phase Cyclin-Dependent Kinases Stabilize the Epstein-Barr Virus BDLF4 Protein To Temporally Control Late Gene Transcription.

Authors:  Yoshitaka Sato; Takahiro Watanabe; Chihiro Suzuki; Yuichi Abe; H M Abdullah Al Masud; Tomoki Inagaki; Masahiro Yoshida; Takeshi Suzuki; Fumi Goshima; Jun Adachi; Takeshi Tomonaga; Takayuki Murata; Hiroshi Kimura
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

10.  Virology. Epstein-Barr virus turns 50.

Authors:  Paul M Lieberman
Journal:  Science       Date:  2014-03-21       Impact factor: 47.728
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.